Among the multiple specialized localization services available in the Life Sciences sector we also come across those referred to as Cognitive debriefing, Backtranslation & Reconciliation and Readability testing. How familiar are you with these linguistic validation services? What does each mean, why is it required and what does it entail?
Translation errors can change the meaning of important content in clinical trial settings resulting in medical complications or the rejection of an entire clinical research project. Ambiguity in translated health questionnaires or instruments can mean that items or questions can be interpreted in more than one way, jeopardizing patient safety and clinical trial data integrity. Unclear and hard to use translated drug leaflets mean that users may not be able to take safe and accurate decisions about their medicines.
In order to help avoid such hazards, IRBs, medical ethical committees, regulatory authorities and applicable legislation require that linguistic validation methods in accordance with FDA and ISPOR guidelines are put in place for translated documentation, such as Patient Reported Outcomes (PROs), Clinician Reported Outcomes (ClinROs), Quality of Life (QOL) questionnaires and package leaflets (PL) of medicinal products.
Cognitive debriefing (also known as pilot testing) is a qualitative method for assessing respondents’ interpretation of an assessment, using a small sample of patients. It helps determine if the respondents understand the questionnaire the same as the original would be understood and tests the level of comprehension of a translation by the target audience. The goal is to ensure that data collected from PROs can be comparable across various language groups used during trials. Steps of the process include:
Backtranslation and reconciliation is a very effective and stringent process that provides additional quality and accuracy assurance for sensitive content, such as Informed Consent Forms (ICFs), questionnaires, surveys and PROs used in clinical trials. It is a linguistic validation process for checking the faithfulness of the target text against the source, focusing mainly on the conceptual and cultural equivalence and less on the linguistic equivalence.
In a back translation, the translated content (forward translation) is translated back into the original language by a separate independent translator. The back translator must be a native speaker of the source language and have excellent command of the target language. He/She should stick more closely to the source that he/she would for a regular translation to accurately reflect the forward translator’s choices, without attempting to explain or clarify confusing statements or to produce a “polished” output.
The next step, “reconciliation”, refers to the process of noting any differences in meaning between the two source versions. The original text is compared to the back translated text and any discrepancies are recorded in a discrepancy report. Discrepancies may be due to ambiguity in the source text, errors introduced by the forward translator, or back translation errors. The reconciler flags issues such as differences in meaning, inconsistent/incorrect terminology, unsuitable register, missing/added information, ambiguities or errors in the backtranslation. Several back and forth between the linguists may be needed to reconcile the versions so that edits and adjustments are made as needed to optimize the final translation.
Readability testing in the fields of pharmaceutics qualifies that the medical information contained in the drug leaflet is usable by potential users of the medication, that is, that they can understand and act upon the information provided. It is a critical step in the process of designing product literature.
Since 2005, manufacturers of medicinal products are legally required to have their patient information leaflets (PILs) readability-tested in order to acquire product approval. According to Directive 2004/27/EC, these leaflets should be “legible, clear and easy to use”, and the manufacturer has to deliver a readability test report to the authorities.
Readability testing may be carried out by the sponsor or CRO, or a language service provider undertaking the localization of the documentation.
The process steps can vary, but stages may include:
The above linguistic validation processes provide an additional safety net for clients in the clinical and pharmaceutical industry helping them meet regulatory requirements and allowing them to focus on their registration and marketing preparation plans.
If you want to learn more about our linguistic validation services, visit our Life Sciences localization page.
Read also:
5 Steps to Success with Clinical Trial Translations
Informed Consent Translations: The Importance of Understanding
The Importance of Accuracy in Medical Translations – The Case Of Willie Ramirez
As we wrap up 2023, let's rewind and revisit our ten most popular blog posts…
https://www.youtube.com/watch?v=204nn9QPJcI The linguistic landscape of China is as vast and diverse as the country itself,…
https://youtu.be/j7SEBtoEASQ The holiday season is a time of joy and celebration, and one of the…
Your globalization and market expansion strategy calls for a very targeted localization approach, even in…
Listen to this article now: https://youtu.be/O7eDRmackvI Language is a powerful tool that reflects and shapes…
Listen to this article now: https://youtu.be/u1WCW4XVXS0 Embarking on global expansion is a strategic leap requiring…